Volume 29, Number 6—June 2023
Dispatch
SARS-CoV-2 Seroprevalence and Cross-Variant Antibody Neutralization in Cats, United Kingdom
Figure 1

Figure 1. Seropositivity of samples included in analysis in study of SARS-CoV-2 seroprevalence and immunity in cats, United Kingdom, April 2020–February 2022. A) Number of samples tested per month. Overall seropositivity across all samples was 3.2% (75/2,309). B) Percentage seropositivity of samples per 3-month period and sample size for each period. VDS, University of Glasgow Veterinary Diagnostic Services laboratory.
Page created: April 13, 2023
Page updated: May 17, 2023
Page reviewed: May 17, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.